These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33898059)

  • 1. Elastosis in Breast Cancer as a Surrogate Marker for Estrogen Receptor Positivity.
    Al Abri S; Al Rawahi A; Rao L
    Oman Med J; 2021 Mar; 36(2):e247. PubMed ID: 33898059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elastosis and steroid receptors in primary breast cancer.
    Lima-de-Almeida FM; Brentani MM; Velludo MA; Goes JC; Baruffi I
    Braz J Med Biol Res; 1985; 18(3):279-83. PubMed ID: 3835979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: A study from North India.
    Marwah N; Batra A; Marwah S; Gupta V; Shakya S; Sen R
    J Cancer Res Ther; 2018; 14(3):537-542. PubMed ID: 29893312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological differentiation in human breast cancer is related to steroid receptors and stromal elastosis.
    Rolland PH; Jacquemier J; Martin PM
    Cancer Chemother Pharmacol; 1980; 5(2):73-7. PubMed ID: 7471317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elastosis in human breast cancer. Correlation with sex steroid receptors and comparison with clinical outcome.
    Glaubitz LC; Bowen JH; Cox EB; McCarty KS
    Arch Pathol Lab Med; 1984 Jan; 108(1):27-30. PubMed ID: 6546333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Immunohistochemical Profile of Breast Cancer for Prognostics and Therapeutic Use.
    Chand P; Garg A; Singla V; Rani N
    Niger J Surg; 2018; 24(2):100-106. PubMed ID: 30283220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative mast cell analysis and hormone receptor study (ER, PR and HER2/neu) in invasive carcinoma of breast.
    Pyla RD; Potekar RM; Patil VS; Reddy AK; Sathyashree KV
    Indian J Pathol Microbiol; 2020; 63(2):200-204. PubMed ID: 32317515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.
    Chen Y; Klingen TA; Wik E; Aas H; Vigeland E; Liestøl K; Garred Ø; Mæhlen J; Akslen LA; Lømo J
    Diagn Pathol; 2014 Dec; 9():230. PubMed ID: 25522915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan.
    Faheem M; Mahmood H; Khurram M; Qasim U; Irfan J
    Ecancermedicalscience; 2012; 6():283. PubMed ID: 23304239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis.
    Jana SH; Jha BM; Patel C; Jana D; Agarwal A
    Indian J Pathol Microbiol; 2014; 57(4):530-6. PubMed ID: 25308002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of elastosis to biochemical and immunohistochemical steroid receptor findings, Ki-67 and epidermal growth factor receptor (EGFR) immunostaining in invasive ductal breast cancer.
    Remmele W; Dietz M; Schmidt F; Schicketanz KH
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(4):319-26. PubMed ID: 8389501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen value as a marker in breast cancer.
    Narita D; Cimpean AM; Anghel A; Raica M
    Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.